Retatrutide and Cyclobenzaprine Combination Safety

Pharmacological Basis for Safety

• The American Association for the Study of Liver Diseases suggests that the combination of retatrutide and cyclobenzaprine appears safe because these medications operate through completely different mechanisms without shared metabolic pathways 1

Metabolic Pathway Analysis

• The European Association for the Study of the Liver notes that cyclobenzaprine undergoes hepatic metabolism via CYP enzymes, but retatrutide is a peptide administered subcutaneously and does not undergo significant hepatic CYP metabolism, indicating no pharmacokinetic interaction is expected 1

Clinical Considerations

• The American College of Clinical Pharmacology recommends monitoring for sedation from cyclobenzaprine, particularly if the patient is on other CNS depressants 1
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that retatrutide causes substantial weight loss, which may affect overall medication dosing requirements for other conditions, although the exact weight loss percentage is not specified in this context 1